Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Lilly Corporate Ctr Drop Code 1094, Lilly Corporate Ctr INDIANAPOLIS IN 46285-0001 |
Tel: | N/A |
Website: | https://www.lilly.com |
IR: | See website |
Key People | ||
David A. Ricks Chairman of the Board, President, Chief Executive Officer | Jacob S. Van Naarden Executive Vice President, Chief Executive Officer - Loxo Oncology at Lilly, President - Lilly Oncology | Anat Ashkenazi Chief Financial Officer, Executive Vice President |
Diogo Rau Executive Vice President, Chief Information and Digital Officer | Alonzo Weems Executive Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer | Anat Hakim Executive Vice President, General Counsel, Secretary |
Eric Dozier Executive Vice President - Human Resources and Diversity | Edgardo Hernandez Executive Vice President, President - Manufacturing Operations | Patrik Jonsson Executive Vice President, President of Lilly Diabetes and Obesity and President of Lilly USA | Johna L. Norton Executive Vice President - Global Quality |
Business Overview |
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. |
Financial Overview |
For the fiscal year ended 31 December 2023, Eli Lilly And Co revenues increased 20% to $34.12B. Net income decreased 16% to $5.24B. Revenues reflect Diabetes-Mounjaro segment increase from $482.5M to $5.16B, Oncology-Verzenio segment increase of 56% to $3.86B, U.S. segment increase of 20% to $21.79B, Europe segment increase of 44% to $6.17B. Net income was offset by Acquired in-Process Research and Deve increase from $908.5M to $3.8B (expense). |
Employees: | 43,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $761,956M as of Dec 31, 2023 |
Annual revenue (TTM): | $34,124M as of Dec 31, 2023 |
EBITDA (TTM): | $11,853M as of Dec 31, 2023 |
Net annual income (TTM): | $5,240M as of Dec 31, 2023 |
Free cash flow (TTM): | -$7,221M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $22,298M as of Dec 31, 2023 |
Shares outstanding: | 950,766,100 as of Feb 28, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |